3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization.

Nephrol Dial Transplant

Unidad de Diálisis, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av. Reyes Católicos 2, 28040 Madrid, Spain.

Published: October 2008

Background: The mesothelium contributes significantly to the functional, structural and homeostatic properties of the peritoneum. Bioincompatible peritoneal dialysis solutions contribute to mesothelial cell loss during chronic peritoneal dialysis. Cell death has been implicated in mesothelial cell loss, but the molecular mechanisms have not been adequately characterized. We now report the modulation of mesothelial cell death by the glucose degradation product 3,4-dideoxyglucosone-3-ene (3,4-DGE).

Methods: Human mesothelial cells were cultured from the effluents of stable dialysis patients. Apoptosis was quantified in cultured mesothelial cells and in peritoneal effluents. Confocal microscopy and inhibitors were used to assess molecular mechanisms.

Results: Peritoneal dialysis solutions with a high content of both glucose and glucose degradation products, but not those with low glucose degradation product content, induced mesothelial cell apoptosis and loss of cell viability in culture and in vivo. 3,4-DGE also induced mesothelial cell apoptosis. Apoptosis induced by peritoneal dialysis solutions and 3,4-DGE was associated with oligomerization of Bax at mitochondria and caspase activation. Bax antagonism prevented caspase activation, apoptosis and cell death. The pancaspase inhibitor zVAD was also protective.

Conclusion: 3,4-DGE and peritoneal dialysis solutions with a high content in glucose degradation products induce mesothelial cell apoptosis by a Bax-dependent mechanism. This could contribute to chronic demesothelization in peritoneal dialysis.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfn273DOI Listing

Publication Analysis

Top Keywords

peritoneal dialysis
24
mesothelial cell
24
dialysis solutions
16
glucose degradation
16
cell death
12
cell apoptosis
12
cell
9
peritoneal
8
mesothelial
8
cell loss
8

Similar Publications

There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).

View Article and Find Full Text PDF

Fungal peritonitis is an uncommon but serious complication that can occur in patients undergoing peritoneal dialysis. It represents a small percentage of all peritonitis cases in these patients. Its diagnosis can be challenging due to the slow growth of fungi and frequent negative culture results.

View Article and Find Full Text PDF

Preservation of residual kidney function (RKF) is important in patients undergoing peritoneal dialysis (PD). We aimed to examine the association between anemia management and residual urine output using data from a nationwide survey of dialysis patients. After excluding patients with anuria at baseline from the Total cohort of 2,712, 659 of 1,640 patients developed anuria during a median follow-up of 2.

View Article and Find Full Text PDF

Will Xylocore be the magic ELIXIR for peritoneal dialysis?

Perit Dial Int

January 2025

Renal Physiology and Dialysis Group, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!